1991
Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo D, DeVita V, Duffey P, Wesley M, Ihde D, Hubbard S, Gilliom M, Jaffe E, Cossman J, Fisher R. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. Journal Of Clinical Oncology 1991, 9: 25-38. PMID: 1702144, DOI: 10.1200/jco.1991.9.1.25.Peer-Reviewed Original ResearchConceptsDaily days 1ProMACE-MOPPComplete remissionProMACE-CytaBOMDay 1Day 8Complete respondersSmall noncleaved-cell lymphomaCo-trimoxazole prophylaxisComplete response rateDouble-strength tabletProMACE-CytaBOM regimenTreatment-related causesTreatment-related mortalityPneumocystis carinii pneumoniaDiffuse aggressive lymphomasPeriod of treatmentDay 1 treatmentCombination chemotherapyAggressive lymphomaCarinii pneumoniaMalignant lymphomaEffective treatmentPatientsResponse rate
1970
Combination Chemotherapy With Nitrogen Mustard, Vincristine, Procarbazine and Prednisone in Previously Treated Patients With Hodgkin's Disease
LOWENBRAUN S, DEVITA V, SERPICK A. Combination Chemotherapy With Nitrogen Mustard, Vincristine, Procarbazine and Prednisone in Previously Treated Patients With Hodgkin's Disease. Blood 1970, 36: 704-717. PMID: 5488687, DOI: 10.1182/blood.v36.6.704.704.Peer-Reviewed Original ResearchConceptsCombination chemotherapyPrior radiotherapyHodgkin's diseaseProgressive Hodgkin's diseaseStage IV diseaseRemission 1Previous therapyComplete responseNitrogen mustardPartial responseTherapy completionSystemic symptomsDrug combinationsChemotherapyPatientsDay 1Drug AdministrationRadiotherapyPrednisoneDiseasePoor toleranceVincristineCycle 1TherapyI.V.